Monitor for actual ATM sales activity, which would confirm capital raising is underway. The offering price relative to the current $7.87 share price will determine immediate dilution impact. Given the company's cash burn rate, expect sales to begin soon to fund ongoing operations and commercialization preparations.
Price Chart
Executive Summary
Kyverna Therapeutics has filed an S-3 shelf registration statement to raise up to $300 million, including $100 million through an ATM offering with Jefferies. The company plans to use proceeds for general corporate purposes, including R&D for its lead CAR-T therapy miv-cel in autoimmune diseases. With a market cap of $450 million, this offering could significantly dilute existing shareholders and signals a need for capital to fund operations and commercialization efforts.
Key Financial Metrics
Key Facts
- Kyverna filed an S-3 shelf registration to raise up to $300 million in various securities
- $100 million of the offering is designated for an ATM (at-the-market) offering through Jefferies
- Company plans to use proceeds for general corporate purposes including R&D, working capital, and potential acquisitions
- Market cap is $450 million, meaning the $100 million ATM offering represents ~22% of current market value
- Company has no revenue and is in late-stage clinical development for autoimmune diseases
- Recent 10-Q shows cash burn of $123.5 million over nine months, indicating need for capital
Financial Impact
Up to $300 million in potential dilution, with $100 million immediately available through ATM offering
Risk Factors
- Significant shareholder dilution from potential issuance of new shares
- Accelerated cash burn could force issuance at unfavorable prices
- Clinical trial results for miv-cel may not meet expectations, reducing valuation
- Competition in CAR-T space for autoimmune diseases
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-126321 |
| Document: kytx-ex4_2.htm | 0001193125-26-126321 |
| Document: kytx_exfilingfees.htm | 0001193125-26-126321 |
| Document: kytx-ex5_1.htm | 0001193125-26-126321 |
| CONTEXT: 10-Q (2025-11-12) | 0001193125-25-277584 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.27 (−9.61%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.27 (−24.61%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.27 (−33.46%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.27 (−46.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.27 (+34.57%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.27 (−41.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.27 (−48.48%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.27 (−53.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers